Dec 20, 2024 · Lilly’s Zepbound, approved in November 2023 as the Indiana-based drug giant’s answer to Novo Nordisk’s Wegovy, showed 21% average weight loss after 72 weeks for its highest dose in its...

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Jan 24, 2025 · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on...

Learn how Wegovy® (semaglutide) can help adults with obesity or excess weight with weight related conditions. Read Important Safety and Prescribing Info, including Boxed Warning.

Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and highlighting the potential for...

Dec 20, 2024 · Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial. Bagsværd, Denmark, 20 December 2024 – Novo Nordisk today announced headline results from REDEFINE 1, a phase 3 trial in the global REDEFINE programme. REDEFINE 1 is a 68-week efficacy and safety trial investigating ...

Achieving 20% or more in weight loss without surgery is our ambition for patients. The global cost of treating obesity-related complications is expected to rise by over $4 trillion by 2035. Why do we gain weight differently? Obesity is influenced by many factors both inside and outside of the body.

Jan 28, 2025 · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over the course of 36 weeks.

Jan 17, 2025 · A high dose of Novo Nordisk’s obesity drug Wegovy caused more weight loss than the approved regimen in a Phase III trial, the company said Friday. However, the data suggest Eli Lilly’s rival GLP-1 drug Zepbound may still have an edge over Wegovy.

Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same class as the blockbuster obesity and diabetes medications, Ozempic and Mounjaro.